European Journal of Molecular & Clinical Medicine

Abstract

Boosted therapy of immunization against SARS-CoV2 has already been certified to
progress for humans all around the world. After having a long breakthrough of a
pandemic, the physiological response of human cells is now presenting as omnipotent
characters for their autoimmune criteria against a viral antigen, types, sub-types, strains,
and modified strains. The molecular genesis is migrated and conducts with a different
pattern of doses but specified in the same dosed to administer by injected protein
derivatives. The viral epitopes and their surface protein are concerned with the activation
of monoclonal antibodies by the artificial secondary immune response. The artificial
immunogenetic is explored by analytical research of several trials of virologists from mid-
August to December 2020.